Biotech Values

[mcbio]

in all seriousness if mnta really knew m-enox would retain sole generic status there would be no reason for this offering

There's a huge difference between confidence and knowing. MNTA can never know for sure what the FDA will do with respect to m-enox despite their confidence (which I think shows through in MNTA's lawsuit against TEVA). That's why, rightly or wrongly, I view today's offering news as a bird in the hand deal. It never hurts to have some extra cash, especially given that MNTA management knows there is no guarantee they will continue to have the sole generic Lovenox even if they are extremely confident.